Aviva’s Novavax NVAX Stock Holding History

Aviva’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,413	Closed	-$300K	–	1000
2021 Q2	$300K	Buy	+1,413	New	+$259K	﹤0.01%	852

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Aviva's NVAX Position: Q3 2021 in Review

Aviva sold out of Novavax (NVAX) in Q3 2021, closing a stake of 1,413 shares — an estimated $300K sold.

Aviva first reported a position in NVAX in Q2 2021 and held it in 1 quarter. The position peaked at $300K in Q2 2021. 442 funds tracked by Wall St. Rank hold NVAX as of Q3 2021.

Aviva reported no remaining Novavax position as of Q3 2021 after selling out during the quarter.
Aviva sold 1,413 Novavax shares in Q3 2021, an estimated $300K.
Aviva first reported a position in Novavax in Q2 2021 and held it in 1 quarter.
Aviva's Novavax position peaked at $300K in Q2 2021.
442 funds tracked by Wall St. Rank held Novavax as of Q3 2021.

Based on Aviva's 13F filing for Q3 2021, filed 12 Nov 2021.